Abstract
Mutation specific antibodies demonstrate the benefit of merging molecular findings with traditional diagnostic expertise. Whether this approach is of sustainable benefit has to be seen. Convincing data on colon carcinoma will be demonstrated at ESMO 2012 with the conclusion to screen patients for BRAFV600E for enrolment in an upcoming clinical trial combining BRAF and EGFR inhibitors.
MeSH terms
-
Antibodies, Monoclonal / genetics*
-
Antibodies, Monoclonal / pharmacology*
-
Biomarkers, Tumor / genetics
-
Humans
-
Molecular Targeted Therapy / methods
-
Mutation
-
Neoplasms / drug therapy*
-
Neoplasms / enzymology
-
Neoplasms / genetics*
-
Proto-Oncogene Proteins B-raf / genetics*
Substances
-
Antibodies, Monoclonal
-
Biomarkers, Tumor
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf